The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Self-citationEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S., Danenberg, K., Domenichini, I., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,551
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,344
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,228
Gastrointestinal stromal tumour
Rubin, B. P., Heinrich, M. C., & Corless, C. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60780-6 · Cited by 1,036
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 952
Self-citationAntonescu, C. R., Besmer, P., Guo, T., Arkun, K., Hom, G., Koryotowski, B., Leversha, M. A., Jeffrey, P. D., Desantis, D., Singer, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2245 · Cited by 836
Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 824
Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730
Self-citationOncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
Greulich, H., Chen, T.-H., Feng, W., Jänne, P. A., Alvarez, J. V., Zappaterra, M., Bulmer, S. E., Frank, D. A., Hahn, W. C., Sellers, W. R., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020313 · Cited by 677
Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K. P., & Hughes, T. P. (2002) · Blood · doi:10.1182/blood.v99.9.3472 · Cited by 649
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Apperley, J. F. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70342-x · Cited by 643
O'Hare, T., Eide, C. A., & Deininger, M. W. N. (2007) · Blood · doi:10.1182/blood-2007-03-066936 · Cited by 641
Weisberg, E., Manley, P. W., Cowan-Jacob, S. W., Hochhaus, A., & Griffin, J. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2126 · Cited by 636
Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., & Mitsudomi, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0714 · Cited by 589
Molyneux, D. H., Hotez, P. J., & Fenwick, A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020336 · Cited by 557
Bell, D. W., Gore, I., Okimoto, R. A., Godin-Heymann, N., Sordella, R., Mulloy, R., Sharma, S. V., Brannigan, B. W., Mohapatra, G., Settleman, J., et al. (2005) · Nature Genetics · doi:10.1038/ng1671 · Cited by 531
Self-citationGoodman, V. L., Rock, E. P., Dagher, R., Ramchandani, R. P., Abraham, S., Gobburu, J. V. S., Booth, B. P., Verbois, S. L., Morse, D. E., Liang, C. Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2328 · Cited by 501
Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E., Borras, A. M., Gale, C.-M., Naumov, G. N., Yeap, B. Y., Jarrell, E., Sun, J., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28656 · Cited by 456
Self-citationShah, N. P., Skaggs, B. J., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30890 · Cited by 418
Giles, F. J., Cortes, J., Jones, D., Bergstrom, D., Kantarjian, H., & Freedman, S. J. (2007) · Blood · doi:10.1182/blood-2006-05-025049 · Cited by 364
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance
Hochhaus, A., & La Rosée, P. (2004) · Leukemia · doi:10.1038/sj.leu.2403426 · Cited by 336
Gambacorti-Passerini, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.20.1641 · Cited by 320
Mahadevan, D., Cooke, L., Riley, C., Swart, R., Simons, B., Della Croce, K., Wisner, L., Iorio, M., Shakalya, K., Garewal, H., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210173 · Cited by 282
Kobayashi, S., Ji, H., Yuza, Y., Meyerson, M., Wong, K.-K., Tenen, D. G., & Halmos, B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1346 · Cited by 272
Shimamura, T., Lowell, A. M., Engelman, J. A., & Shapiro, G. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0933 · Cited by 259
Self-citationLi, D., Shimamura, T., Ji, H., Chen, L., Haringsma, H. J., McNamara, K., Liang, M.-C., Perera, S. A., Zaghlul, S., Borgman, C. L., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.06.005 · Cited by 238
Self-citationGriswold, I. J., MacPartlin, M., Bumm, T., Goss, V. L., O'Hare, T., Lee, K. A., Corbin, A. S., Stoffregen, E. P., Smith, C., Johnson, K., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02202-05 · Cited by 200
Ogino, A., Kitao, H., Hirano, S., Uchida, A., Ishiai, M., Kozuki, T., Takigawa, N., Takata, M., Kiura, K., & Tanimoto, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0681 · Cited by 194
Targeted CML therapy: controlling drug resistance, seeking cure
O’Hare, T., Corbin, A. S., & Druker, B. J. (2006) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.11.002 · Cited by 178
Godin-Heymann, N., Bryant, I., Rivera, M. N., Ulkus, L., Bell, D. W., Riese, D. J., Settleman, J. E., & Haber, D. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4625 · Cited by 165
Self-citationSteeghs, N., Nortier, J. W. R., & Gelderblom, H. A. J. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9227-1 · Cited by 162
Cancer-specific mutations in phosphatidylinositol 3-kinase
Vogt, P. K., Kang, S., Elsliger, M., & Gymnopoulos, M. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.05.005 · Cited by 157
Peng, C., Brain, J. M., Hu, Y., Goodrich, A., Kong, L., Grayzel, D., Pak, R. H., Read, M. A., & Li, S. (2007) · Blood · doi:10.1182/blood-2006-10-054098 · Cited by 155
Regales, L., Balak, M. N., Gong, Y., Politi, K. A., Sawai, A., Le, C. H., Koutcher, J. A., Solit, D. B., Rosen, N. X., Zakowski, M. F., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000810 · Cited by 133
Resistance to imatinib mesylate in chronic myeloid leukaemia
Melo, J. V., & Chuah, C. T. H. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.07.010 · Cited by 132
Yamasaki, F., Johansen, M. J., Zhang, D., Krishnamurthy, S., Felix, E. A., Bartholomeusz, C., Aguilar, R. J., Kurisu, K., Mills, G. B., Hortobágyi, G. N., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3020 · Cited by 129
Fletcher, J. A., & Rubin, B. P. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.010 · Cited by 121
Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR Inhibitors
Haber, D. A., Bell, D. W., Sordella, R., Kwak, E. L., Godin-Heymann, N., Sharma, S. V., Lynch, T. J., & Settleman, J. E. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.043 · Cited by 121
Self-citationMolecular mechanisms of resistance to STI571 in chronic myeloid leukemia
Gorre, M. E., & Sawyers, C. L. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200207000-00007 · Cited by 118
Sawabu, T., Seno, H., Kawashima, T., Fukuda, A., Uenoyama, Y., Kawada, M., Kanda, N., Sekikawa, A. M., Fukui, H., Yanagita, M., et al. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20211 · Cited by 112
Protein Kinases as Targets for Cancer Treatment
Giamas, G., Stebbing, J., Vorgias, C. E., & Knippschild, U. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.8.1005 · Cited by 80
Resistance in the land of molecular cancer therapeutics
Shannon, K. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00101-0 · Cited by 67
Sleijfer, S., Wiemer, E. A. C., Seynaeve, C., & Verweij, J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-719 · Cited by 62
Peng, C., Li, D., & Li, S. (2007) · Cell Cycle · doi:10.4161/cc.6.18.4722 · Cited by 44
Jilani, I. B., Kantarjian, H. M., Gorre, M. E., Cortes, J. E., Ottmann, O. G., Bhalla, K. N., Giles, F. J., & Albitar, M. X. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.08.009 · Cited by 25
Treating Imatinib-Resistant Leukemia: The Next Generation Targeted Therapies
Burgess, M. R., & Sawyers, C. L. (2006) · The Scientific World JOURNAL · doi:10.1100/tsw.2006.184 · Cited by 24
Cited by
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Self-citationTargeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M., Solomon, B. J., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,309
Self-citationVillanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., Wubbenhorst, B., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,259
Metadata
- Authors
- Engelman, J. A., & Settleman, J.
- Venue
- Current Opinion in Genetics & Development
- Publisher
- Elsevier BV
- Published
- 2008-02
- Volume
- 18
- Issue
- 1
- Pages
- 73-79
- ISSN
- 0959-437X (ISSN-L)
- OpenAlex
- W2030440427
- Cited by
- 284
- References
- 57
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.